Abstract
Immunomodulatory agents that target PD-1 and its ligand (PD-L1) are being increasingly used in the management of lung cancer. Potential immune-related adverse events include dermatological complications which mostly are of low grade severity. The use of immune checkpoint inhibitors may lead to the exacerbation of autoimmune conditions. We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer.
MeSH terms
-
Adenocarcinoma / immunology
-
Adenocarcinoma / pathology
-
Adenocarcinoma / therapy*
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents / therapeutic use
-
B7-H1 Antigen / immunology
-
Calcitriol / analogs & derivatives
-
Calcitriol / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Cigarette Smoking
-
Disease Progression
-
ErbB Receptors / genetics*
-
Exons / genetics
-
Humans
-
Male
-
Mometasone Furoate / therapeutic use
-
Neoplasm Metastasis
-
Phototherapy
-
Psoriasis / etiology
-
Psoriasis / prevention & control*
-
Sequence Deletion / genetics
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
B7-H1 Antigen
-
Mometasone Furoate
-
calcipotriene
-
ErbB Receptors
-
Calcitriol